August 28, 2024 01:40 PM EDT

Regeneron sues Sandoz to halt biosimilar to its blockbuster eye drug

Katherine Lewin

News Reporter

Regeneron is going after Sandoz in a New Jersey federal court over Sandoz’s recently-approved drug Enzeevu, a biosimilar to Regeneron’s blockbuster eye treatment Eylea. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Regeneron sues Sandoz to halt biosimilar to its blockbuster eye drug

Katherine Lewin

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

You bet your life: After I was diagnosed with a rare cancer, I discovered how a small band of physician-scientists ...

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

A VC-backed genetic testing startup to 'consider' making an offer to buy 23andMe

Biotech VC firm outlines plans for $100M fund

In surprise, study suggests Covid mRNA vaccines may boost cancer immunotherapy efficacy

Breaking down silos with a new quantitative approach to drug development

Re­gen­eron sues San­doz to halt biosim­i­lar to its block­buster eye drug

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Regeneron sues Sandoz to halt biosimilar to its blockbuster eye drug